Fingolimod

BreastfeedingPediatric
  • TRADE NAME: Gilenya (Novartis)
  • INDICATIONS: Multiple sclerosis
  • CLASS: Immunosuppressant
  • HALF-LIFE: 6–9 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

BCG Vaccine, Beta blockers, Class Ia antiarrhythmics, Class III antiarrhythmics, Conivaptan, Cyproterone, Denosumab, Digoxin, Diltiazem, Dronedarone, Ketoconazole, Leflunomide, Live vaccines, Natalizumab, PEG-Interferon, Pimecrolimus, QT prolonging drugs, Roflumilast, Sipuleucel-T, Tacrolimus, Tocilizumab, Trastuzumab, Typhoid Vaccine, Verapamil, Yellow Fever Vaccine

PREGNANCY CATEGORY: C

Contra-indicated in patients with recent (within the last 6 months) occurrence of: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure; history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker; baseline QT interval ≥500 ms; or is receiving treatment with Class Ia or Class III anti-arrhythmic drugs.

Our database has 82 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
HEMATOLOGIC
OCULAR
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fingolimod in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 11/14/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric